EXPO Stock Analysis: Exponent | NASDAQ
Engineering & Construction | NASDAQ, USA | Market Cap: 3.240m USD | 12M Return: -4.5% | US30214U1025 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 33.3M
EPS Trend: 78.8%
Qual. Beats: 1
Rev. Trend: 96.0%
Qual. Beats: 4
Warnings
No concerns identified
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Exponent, Inc. (NASDAQ: EXPO) is a U.S.-based science and engineering consulting firm founded in 1967 and headquartered in Menlo Park, California. Originally named The Failure Group, the company rebranded in 1998 and operates through two reporting segments: Engineering and Other Scientific, and Environmental and Health. Its services span a broad multidisciplinary range, including biomechanics, biomedical engineering, civil and structural engineering, construction consulting, electrical and computer science, human factors, materials and corrosion engineering, mechanical engineering, thermal sciences, vehicle engineering, chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences, and health sciences. In addition to proactive and reactive product safety work, the firm provides litigation support and technical/regulatory consulting to clients across a wide range of end markets, including chemical, construction, consumer products, energy, food and beverage, government, life sciences, insurance, manufacturing, technology, industrial equipment, and transportation. Listed in the Industrials sector under the Research & Consulting Services sub-industry, Exponents business model centers on deploying highly credentialed scientists and engineers for failure analysis, expert testimony, and regulatory advisory engagements, a niche in which billings are typically driven by hourly technical rates and project complexity rather than by volume-based metrics common to industrial peers.
- Product liability litigation drives Engineering segment revenue growth
- Tighter chemical regulations boost Environmental and Health consulting demand
- Aggressive buybacks and dividends support per-share earnings growth
| Net Income: 111.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA 0.71 > 1.0 |
| NWC/Revenue: 24.38% < 20% (prev 51.86%; Δ -27.48% < -1%) |
| CFO/TA 0.18 > 3% & CFO 118.1m > Net Income 111.8m |
| Net Debt (14.1m) to EBITDA (153.3m): 0.09 < 3 |
| Current Ratio: 1.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.0m) vs 12m ago -5.04% < -2% |
| Gross Margin: 24.60% > 18% (prev 56.74%; Δ -32.15% > 0.5%) |
| Asset Turnover: 89.57% > 50% (prev 73.81%; Δ 15.77% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.24 (Total Current Assets 312.0m - Total Current Liabilities 157.8m) / Total Assets 652.7m |
| B: 1.07 (Retained Earnings 696.4m / Total Assets 652.7m) |
| C: 0.20 (EBIT TTM 143.1m / Avg Total Assets 706.1m) |
| D: 0.79 (Book Value of Equity 288.6m / Total Liabilities 364.1m) |
| Altman-Z'' = 7.22 = AAA |
| DSRI: 1.13 (Receivables 218.5m/171.0m, Revenue 632.5m/560.5m) |
| GMI: 2.31 (GM 56.74% / 24.60%) |
| AQI: 1.23 (AQ_t 0.31 / AQ_t-1 0.25) |
| SGI: 1.13 (Revenue 632.5m / 560.5m) |
| TATA: -0.01 (NI 111.8m - CFO 118.1m) / TA 652.7m) |
| Beneish M = -1.50 (Cap -4..+1) = CCC |
As of August 14, 2026, the stock is trading at USD 68.21 with a total of 385,063 shares traded. Over the past week, the price has changed by +3.02%, over one month by +7.27%, over three months by +25.72% and over the past year by -4.45%.
Current recommended Stop Loss: 62.60 (which is 8.2% or 2.5 ATR below the current price).
Exponent has received a consensus analysts rating of 3.67. Therefore, it is recommended to hold EXPO.
- StrongBuy: 1
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 84 | 23.1% |
P/E Trailing = 29.6844
P/E Forward = 29.3255
P/S = 5.7131
P/B = 11.4011
P/EG = 2.0325
Revenue TTM = 632.5m USD
EBIT TTM = 143.1m USD
EBITDA TTM = 153.3m USD
Long Term Debt = 74.0m USD (estimated: total debt 80.7m - short term 6.76m)
Short Term Debt = 6.76m USD (from shortTermDebt, last quarter)
Debt = 80.7m USD (from shortLongTermDebtTotal, last quarter) (leases 81.0m already included)
Net Debt = 14.1m USD (calculated: Debt 80.7m - CCE 66.6m)
Enterprise Value = 3.25b USD (3.24b + Debt 80.7m - CCE 66.6m)
Interest Coverage Ratio = unknown (Ebit TTM 143.1m / Interest Expense TTM 0.0)
EV/FCF = 29.98x (Enterprise Value 3.25b / FCF TTM 108.6m)
FCF Yield = 3.34% (FCF TTM 108.6m / Enterprise Value 3.25b)
FCF Margin = 17.16% (FCF TTM 108.6m / Revenue TTM 632.5m)
Net Margin = 17.67% (Net Income TTM 111.8m / Revenue TTM 632.5m)
Gross Margin = 24.60% ((Revenue TTM 632.5m - Cost of Revenue TTM 476.9m) / Revenue TTM)
Gross Margin QoQ = 20.64% (prev 28.61%)
Tobins Q-Ratio = 4.99 (Enterprise Value 3.25b / Total Assets 652.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 80.7m)
Taxrate = 28.27% (44.1m / 155.8m)
NOPAT = 102.6m (EBIT 143.1m * (1 - 28.27%))
Current Ratio = 1.98 (Total Current Assets 312.0m / Total Current Liabilities 157.8m)
Debt / Equity = 0.28 (Debt 80.7m / totalStockholderEquity, last quarter 288.6m)
Debt / EBITDA = 0.09 (Net Debt 14.1m / EBITDA 153.3m)
Debt / FCF = 0.13 (Net Debt 14.1m / FCF TTM 108.6m)
Total Stockholder Equity = 355.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 15.83% (Net Income 111.8m / Total Assets 652.7m)
RoE = 31.48% (Net Income TTM 111.8m / Total Stockholder Equity 355.0m)
RoCE = 33.35% (EBIT 143.1m / Capital Employed (Equity 355.0m + L.T.Debt 74.0m))
RoIC = 21.84% (NOPAT 102.6m / Invested Capital 470.0m)
WACC = 7.13% (E(3.24b)/V(3.32b) * Re(7.31%) + D(80.7m)/V(3.32b) * Rd(0.0%) * (1-Tc(0.28)))
Discount Rate = 7.31% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -76.91 | Cagr: -2.13%
[DCF] Terminal Value 73.92% ; FCFF base≈113.5m ; Y1≈104.2m ; Y5≈92.2m
[DCF] Fair Price = 29.87 (EV 1.46b - Net Debt 14.1m = Equity 1.45b / Shares 48.5m; r=8.35% [WACC [floored]]; 5y FCF grow -10.23% → 2.50% )
EPS Correlation: 78.82 | EPS CAGR: 3.41% | SUE: 2.55 | # QB: 1
Revenue Correlation: 96.02 | Revenue CAGR: 6.96% | SUE: 1.86 | # QB: 4
EPS current Quarter (2026-09-30): EPS=0.65 | Chg30d=+1.37% | Revisions=-50% | Analysts=4
EPS current Year (2026-12-31): EPS=2.51 | Chg30d=+1.76% | Revisions=-17% | GrowthEPS=+21.4% | GrowthRev=+13.0%
EPS next Year (2027-12-31): EPS=2.84 | Chg30d=+2.92% | Revisions=+29% | GrowthEPS=+13.1% | GrowthRev=+8.0%
[Analyst] Revisions Ratio: -15% (up=4, down=6)